These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 131398)

  • 21. [The effect of an angiotensin antagonist on blood pressure, renin and aldosterone secretion and its pathogenetic importance].
    Beckerhoff R
    Schweiz Med Wochenschr Suppl; 1978; (7):1-24. PubMed ID: 349683
    [No Abstract]   [Full Text] [Related]  

  • 22. [SAR1, ALA8]-Angiotensin II (saralasin): a symposium. Introduction.
    Vaughan ED; Peach MJ
    Kidney Int Suppl; 1979 Mar; (9):S1-2. PubMed ID: 289858
    [No Abstract]   [Full Text] [Related]  

  • 23. [Significance of renin-angiotensin system inhibitors in the diagnosis of hypertension].
    Stumpe KO; Kolloch RE; Overlack A
    Med Welt; 1977 Oct; 28(41):1645-9. PubMed ID: 927124
    [No Abstract]   [Full Text] [Related]  

  • 24. Hypertension, the adrenal and the kidney: lessons from pharmacologic interruption of the renin-angiotensin system.
    Hollenberg NK; Williams GH
    Adv Intern Med; 1980; 25():327-61. PubMed ID: 6153859
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of saralasin on plasma aldosterone in hypertensive man.
    Brown RD; Tucker R; Tue K; Wisgerhof M; Salassa R
    J Lab Clin Med; 1978 Mar; 91(3):473-9. PubMed ID: 627750
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effect of the angiotensin antagonist saralasin (1-sar-8-ala-angiotensin II) on the blood pressure in secondary hypertension].
    Beckerhoff R; Vetter W; Furrer J; Tuma J; Zàruba K; Vetter H; Siegenthaler W
    Schweiz Med Wochenschr; 1976 Dec; 106(49):1738-41. PubMed ID: 1013696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Current theories on the etiology of renovascular hypertension].
    Markov KhM
    Patol Fiziol Eksp Ter; 1978; (1):5-15. PubMed ID: 643334
    [No Abstract]   [Full Text] [Related]  

  • 28. [Saralasin in subjects with low renin arterial hypertension].
    Frisina N; Buemi M; Lasco A; Macrí I; Ciraolo O; Nicita Mauro V; Costa G
    Boll Soc Ital Biol Sper; 1980 Jul; 56(13):1367-73. PubMed ID: 7004464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Saralasin infusion in renovascular and essential hypertension.
    Thien T; Hoefnagels WH
    Neth J Med; 1980; 23(2):68-73. PubMed ID: 6990282
    [No Abstract]   [Full Text] [Related]  

  • 30. Saralasin in human hypertension: the early experience.
    Brunner HR; Laragh JH
    Kidney Int Suppl; 1979 Mar; (9):S36-43. PubMed ID: 289862
    [No Abstract]   [Full Text] [Related]  

  • 31. [Hemodynamics, renin and aldosterone following angiotensin II blockade and sodium chloride deficiency in hypertensive subjects].
    Beyer J; Liebau G; Steiner B; Schick K; Hayduk K
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():212-3. PubMed ID: 613577
    [No Abstract]   [Full Text] [Related]  

  • 32. The place of renin in the mechanism of hypertension in chronic renal disease.
    Peart WS
    Clin Nephrol; 1975 Oct; 4(4):138-43. PubMed ID: 1104233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin antagonists as diagnostic and pharmacologic tools.
    Pettinger WA; Mitchell HC
    Prog Biochem Pharmacol; 1976; 12():203-13. PubMed ID: 798203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late hypertension following renal allotransplantation.
    Pollini J; Guttmann RD; Beaudoin JG; Morehouse DD; Klassen J; Knaack J
    Clin Nephrol; 1979 Apr; 11(4):202-12. PubMed ID: 378492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blockade of renin or angiotensin for understanding human hypertension: a comparison of propranolol, saralasin and converting enzyme blockade.
    Laragh JH; Case DB; Wallace JM; Keim H
    Fed Proc; 1977 Apr; 36(5):1781-7. PubMed ID: 191300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Production of sustained hypertension by chronic intrarenal norepinephrine infusion in conscious dogs.
    Katholi RE; Carey RM; Ayers CR; Vaughan ED; Yancey MR; Morton CL
    Circ Res; 1977 May; 40(5 Suppl 1):I118-26. PubMed ID: 870220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exchangeable sodium and saralasin-blocking, plasma renin and aldosterone in pre- and postoperative young patients with aortic coarctation.
    Sehested J; Kornerup HJ; Pedersen EB
    Eur Heart J; 1982 Apr; 3(2):179-83. PubMed ID: 7044785
    [No Abstract]   [Full Text] [Related]  

  • 38. Renin and aldosterone and the pathogenesis of hypertensive vascular damage.
    Gavras H; Brunner HR; Laragh JH
    Prog Cardiovasc Dis; 1974; 17(1):39-49. PubMed ID: 4365952
    [No Abstract]   [Full Text] [Related]  

  • 39. Mineralocorticoids and the regulation of sodium metabolism in normal and hypertensive pregnancy: a review.
    Ehrlich EN; Nolten WE; Lindheimer MD
    Clin Exp Hypertens (1978); 1980; 2(5):803-19. PubMed ID: 6159142
    [No Abstract]   [Full Text] [Related]  

  • 40. Antihypertensive effect of spironolactone in essential, renal and mineralocorticoid hypertension.
    Mantero F; Armanini D; Urbani S
    Clin Sci Mol Med Suppl; 1973 Aug; 45 Suppl 1():219s-24. PubMed ID: 4522169
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.